SEC Filing Summary: Salarius Pharmaceuticals, Inc. (SLRX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. on August 22, 2025. The filing relates to a corporate event concerning the company's capital raising activities under an existing registration statement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the mechanics of a securities offering rather than financial performance results.
Material Changes and Events
- Prospectus Supplement Filed: On August 22, 2025, the Company filed a prospectus supplement to its effective Form S-3 Registration Statement (File No. 333-266589).
- Offering Details: The supplement covers the registered offering of up to $2,600,000 of shares of common stock (par value $0.0001 per share).
- Agreement: The offering is conducted pursuant to an At-the-Market Offering Agreement dated February 5, 2021, with Ladenburg Thalmann & Co. Inc.
- Legal Opinion: A legal opinion from Hogan Lovells US LLP regarding the validity of the shares was filed as Exhibit 5.1.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the securities offering. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the total number of shares sold under the At-the-Market Offering Agreement since the filing of the prospectus supplement.
- Confirm the current cash balance and burn rate in the most recent 10-Q or 10-K to assess the necessity of this $2.6 million offering.
- Review the pricing of shares sold under the ATM program to evaluate potential dilution impact.
- Check for any subsequent 8-K filings regarding the completion or termination of this specific offering tranche.